Skip to main content

Table 2 Effectiveness of CoronaVac against symptomatic and severe COVID-19, among pregnant women aged 18–49 years in Brazil (comparison of symptomatic and severe cases with test-negative controls)

From: CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study

Sinovac-CoronaVac
Vaccination status Unadjusted odds ratio (95% CI) Unadjusted# odds ratio (95% CI) Adjusted odds ratio (95% CI) Adjusted* VE% (95% CI) p-value
Symptomatic COVID-19
 Unvaccinated Ref Ref Ref Ref  
 One dose < 13 days 0.94 (0.77–1.14) 1.35 (1.10–1.66) 1.35 (1.09–1.68) 0.006
 Partially vaccinated (one dose ≥ 14 days) 0.64 (0.53–0.77) 1.00 (0.82–1.22) 0.94 (0.76–1.18) 5.02 (–18.22– 23.69) 0.645
 Two doses ≥ 14 days 0.42 (0.35–0.50) 0.69 (0.57–0.83) 0.59 (0.47–0.72) 40.97 (27.07– 52.22) < 0.001
Severe COVID-19
 Unvaccinated Ref Ref Ref Ref  
 One dose < 13 days 1.38 (0.87–2.19) 1.64 (1.01–2.65) 1.42 (0.83–2.43) 0.192
 Partially vaccinated (one dose ≥ 14 days) 0.30 (0.13–0.69) 0.38 (0.16–0.87) 0.32 (0.13–0.80) 67.74 (20.00–87.00) 0.015
 Two doses ≥ 14 days 0.15 (0.06–0.37) 0.20 (0.08–0.50) 0.14 (0.05–0.40) 85.39 (59.44– 94.80) < 0.001
  1. VE Vaccine effectiveness
  2. *Adjusted for: Age, race, co-morbidities, region of residency, IBP and time
  3. #Adjusted for time